Regeneresen

In alternative medicine , Regeneresen were preparations containing animal ribonucleic acids and ribonucleic acids from yeast. As of 2012, they are no longer approved as finished medicinal products in Germany. They were mainly used for degenerative diseases of the musculoskeletal system, diseases of the nervous system and the sensory organs, disorders of the immune system and all diseases that are associated with a primary disruption of protein synthesis. Their effect was controversial and not scientifically proven.

The so-called RNA therapy goes back to the German chemist Hanns Dyckerhoff. Your users believe that, at the latest from a certain age or generally with diseased organs, the number of organ-specific, non-coding RNAs that are supposed to modulate and control protein synthesis is no longer sufficient and this can be substituted by administration of bovine and yeast RNA of the same cell type.

Composition, application

According to the manufacturer, Dyckerhoff Pharma , the preparations contained so-called organ-specific ribonucleic acids from beef and ribonucleic acids from yeast . The Regeneresen had names like Regeneresen kidney , Regeneresen cerebellum , etc.

The preparations were administered intramuscularly to the patients .

Effectiveness and scientific testing

Therapy experiences from observational studies with Regeneresen were first published in 1957 for various chronic diseases such as pancreatic sclerosis, bronchial asthma, osteoarthritis and arthritis.

According to the manufacturer, the Regeneresen preparation AU 4 contained ribonucleic acids from the auditory tract, auditory nerve, auditory center, cattle inner ear and yeast. It has only been tested under controlled conditions in a clinical study on patients with tinnitus and hearing loss after an impact trauma.

A summary of conducted controlled clinical studies and observational studies with RN 13 , AU 4 , Osteochondrin S and other varieties has now been published.

Drug safety

Transmission of BSE

A study from 1997 examined a manufacturing process on which Regeneresen production is based and came to the conclusion that Regeneresen are safe with regard to the transmission of BSE and that there is no risk of infection.

In 1996, in connection with a study in Austria, a case of Creutzfeldt-Jakob 's disease (CJD) was observed in a patient who had been injected with regeneration of animal origin (including RNA from brain tissue) for ten years . The study was commissioned by an Austrian health authority in connection with the increase in BSE diseases in Great Britain and was intended to examine whether the CJD diseases registered in Austria could be related to a transmission of the BSE pathogen. The study comes to the conclusion that none of the cases of illness registered in Austria are due to medical intervention and that all cases are attributable to the sporadic CJD: "No case had an unequivocal family history or recognized risk for iatrogenic transmission; thus all presented as sporadic CJD ".

Contraindications and side effects

According to the manufacturer Dyckerhoff Pharma , patients with overt gout, phenylketonuria and other breakdown defects of phenylalanine should not be treated. In rare cases, hypersensitivity reactions (itchy skin, reddening of the skin) would occur.

literature

General

• N. Goossens: On the mechanism of action and toxicity of regeneresen. In: Med world. 32, Aug 6, 1960, pp. 1636-1640.

To use

• Gerhard Gerster: Treatment options with ribonucleic acids in children with neurological deficits. In: Journal for Orthomolecular Medicine. Cologne 1995.
• Gerhard Schettler, Gerhard Gerster: Treatment of advanced neural muscle atrophy with ribonucleic acids. In: Journal for Orthomolecular Medicine. 3, 2, Cologne 1995, pp. 146-153.
• Gerhard Jakobi: Case studies with a focus on eye diseases. In: Expert talk. Ralf Reglin Verlag, Cologne 1997, ISBN 3-930620-15-4 , pp. 7-17.
• Detlev Thilo-Körner: Cerebral cavernous hemangioma with increasing blindness. In: Expert talk. Ralf Reglin Verlag, Cologne 1997, ISBN 3-930620-15-4 , pp. 18-35.
• G. Linneweber: RNA in tumor therapy - improving the tolerance of chemotherapy. In: empirical medicine. 42, 1993, pp. 207-211.

Individual evidence

1. ↑ H. Dyckerhoff: On the nucleic acids as effectors for preservation of type and individual and on their therapeutic potentialities. (About the nucleic acids as effectors for the preservation of species and individuals and about their therapeutic potencies). In: Hippocrates. 31, 1960, pp. 101-106. PMID 13818987 . (molekulartherapie.de)
2. ↑ H. Dyckerhoff: Biologically active ribonucleic acids (RNS) for the treatment of protein build-up disorders by increasing protein biosynthesis in chronic and degenerative diseases. Müller Göppingen Chemical-Pharmaceutical Factory, new edition, Cologne / Göppingen 1984. (molekulartherapie.de)
3. ^ HG Rietschel: The Effect of Regeneresen. In: Med Klin. (Munich), 52 (48), Nov 29, 1957, pp. 2080-2081. PMID 13493022 . (molekulartherapie.de)
4. ↑ History of Regeneresen. (dyckerhoff-pharma.de)
5. ↑ M. Pilgramm, K. Schumann: On the necessity of rheologically effective as well as vasoactive and metabolically active substances in the initial treatment of acute pop trauma. In: ENT. 34 (10), Oct 1986, pp. 424-428. PMID 2432041
6. ↑ KD Rainsford, MC Powanda, MW Whitehouse (Eds.): Novel Natural Products - Therapeutic Effects in Pain, Arthritis and Gastrointestinal Diseases. 2015, ISBN 978-3-0348-0927-6 , pp. 35-89.
7. ^ Richard H. Kimberlin: Results and Discussion of a Process Validation Study of the Removal of TSE (Scrapie) Infectivity During the Manufacture of Regeneresen. Edinburgh (UK), September 1997. (molekulartherapie.de)
8. ↑ JA Hainfellner: Creutzfeldt-Jakob disease in Austria. In: J Neurol Neurosurg Psychiatr. 61, 1996, pp. 139-142. PMID 8708680 . (jnnp.bmj.com)
9. ↑ Information about the therapy concept with Regeneresen , Dyckerhoff Pharma, Cologne 2012, p. 4.

Remarks

1. ↑ The common name for ribonucleic acid in the 1960s was "RNA", hence "RNA therapy". Today, however, the English name RNA is common.